Global Esophageal Cancer Market – Overview
The global esophageal cancer market is showing the steady growth; mainly owing to increase in patient population. Also, the chances of develop esophageal cancer increases with age and the occurrence of esophageal cancer are much low in children and young adults in comparison to people over 55 year.
According to report published by Cancer Research UK, in 2014, it is estimated that around 8,919 incidence of esophageal cancer found in the United Kingdom. These rising number of esophageal cancer create an opportunity for the player to introduce innovative treatment option.
Considering all these factors the esophageal cancer market size is expected to reach $ 1000.1 million by the end of 2023, this market is projected to growing at a CAGR of ~ 8.7 % during 2017-2023.
Companies are continuously invent new treatment to capture the global market. Thus players invest more in merger and acquisition activities. In this regards, Leap Therapeutics, Inc. announced the completion of its merger with Macrocure Ltd. This acquisition provide access to Macrocure for Leap Therapeutics' pipeline candidates - DKN-01 and TRX518.These companies are more investing in research and development program to provide the best treatment option, which help them to keep ahead with their competitor.
In 2016, CANbridge Life Sciences has signed an agreement with Boehringer Ingelheim for the manufacture of CAN-017, an ErbB3 (HER3) inhibitory antibody to treat esophageal squamous cell cancer. Increasing in the consumption of smoking, alcohol, leads the incidence of esophageal cancer.
Global Esophageal Cancer Market - Regional Analysis
Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche (Switzerland), Bristol-Myers Squibb Company (U.S.), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb (U.S.), GlaxoSmithKline Plc. (U.K), Novartis AG (Switzerland), Johnson & Johnson (U.S.), Gilead Sciences, Inc. (U.S.), Merck & Co., Inc. (U.S.) are some of the leading players at the cutting edge of the competition in the market of esophageal cancer, globally.
The market of esophageal cancer is much higher in the Americas region attribute to high rate of tobacco, alcohol, very hot drinks, poor diet, and chewing betel nut. According to report published by American Cancer Society, in 2018, it is estimated that around 17,290 new cases of esophageal cancer diagnosed in Americas which include 13,480 of men and 3,810 of women and around 15,850 will be die. Additionally, In the United States, up to 200,000 people die each year from smoking-related illnesses that leads to incidence of esophageal cancer in this region. The government have more focus towards research and development for introducing the best treatment for their population.
https://www.marketresearchfuture.com/reports/esophageal-cancer-market-3280